October 18, 2018 09:05 AM EDT
Pharma

Am­gen sharp­ens fo­cus on ge­net­ic se­quenc­ing with $66M in­vest­ment

ENDPOINTS

Re­in­forc­ing its abil­i­ty to iden­ti­fy and val­i­date dis­ease tar­gets, Am­gen $AMGN on Thurs­day said it would fork out £50 mil­lion ($66 mil­lion) to buy shares …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times